Qube Research & Technologies (QRT)
CARM

Qube Research & Technologies (QRT)’s Carisma Therapeutics CARM Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-16,584
Closed -$16.3K – 3480
2024
Q3 		$16.3K Sell
16,584
-15,068
-48% -$16.3K ﹤0.01% 2991
2024
Q2 		$48.1K Buy
+31,652
New +$47.2K ﹤0.01% 2751
2023
Q1 		– Sell
-684
Closed -$8.33K – 2568
2022
Q4 		$8.33K Sell
684
-6,537
-91% -$68.6K ﹤0.01% 2293
2022
Q3 		$61K Sell
7,221
-1,271
-15% -$17.3K ﹤0.01% 2095
2022
Q2 		$138K Buy
+8,492
New +$97.2K ﹤0.01% 1828
2021
Q2 		– Sell
-7,801
Closed -$406K – 2303
2021
Q1 		$406K Sell
7,801
-8,714
-53% -$411K 0.01% 1300
2020
Q4 		$446K Sell
16,515
-15,090
-48% -$383K 0.01% 1174
2020
Q3 		$885K Buy
31,605
+27,407
+653% +$548K 0.01% 843
2020
Q2 		$60K Buy
+4,198
New +$56.6K ﹤0.01% 1578
2020
Q1 		– Sell
-12,562
Closed -$261K – 1171
2019
Q4 		$261K Buy
+12,562
New +$289K 0.01% 1287

Other funds holding CARM

MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIIC
AJU IB Investment Company Seoul, South Korea $30.5M AUM 128.96% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Qube Research & Technologies (QRT)'s CARM Position: Q4 2024 in Review

Qube Research & Technologies (QRT) sold out of Carisma Therapeutics (CARM) in Q4 2024, closing a stake of 16,584 shares — an estimated $16.3K sold.

Qube Research & Technologies (QRT) first reported a position in CARM in Q4 2019 and held it in 10 quarters. The position peaked at $885K in Q3 2020. 41 funds tracked by Wall St. Rank hold CARM as of Q4 2024.

  • Qube Research & Technologies (QRT) reported no remaining Carisma Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Qube Research & Technologies (QRT) sold 16,584 Carisma Therapeutics shares in Q4 2024, an estimated $16.3K.
  • Qube Research & Technologies (QRT) first reported a position in Carisma Therapeutics in Q4 2019 and held it in 10 quarters.
  • Qube Research & Technologies (QRT)'s Carisma Therapeutics position peaked at $885K in Q3 2020.
  • 41 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q4 2024.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q4 2024, filed 14 Feb 2025.